Results 11 to 20 of about 212 (104)

Research priorities for characterising Bundibugyo virus.

Lancet, The
Henry Kyobe Bosa, Patrick D M C Katoto, Kyeng Mercy   +2 more
exaly   +3 more sources

One-Step Reverse-Transcription FRET-PCR for Differential Detection of Five Ebolavirus Species. [PDF]

PLoS ONE, 2015
Ebola is an emerging infectious disease caused by a deadly virus belonging to the family Filoviridae, genus Ebolavirus. Based on their geographical distribution, Ebolavirus has been classified into total five species so far, mainly Zaire, Sudan, Taï ...
Guangwu Lu, Jilei Zhang, Chuntao Zhang, Xiaolu Li, Dawei Shi, Zhaopeng Yang, Chengming Wang   +6 more
doaj   +1 more source

Development and evaluation of a panel of filovirus sequence capture probes for pathogen detection by next-generation sequencing. [PDF]

PLoS ONE, 2014
A detailed understanding of the circulating pathogens in a particular geographic location aids in effectively utilizing targeted, rapid diagnostic assays, thus allowing for appropriate therapeutic and containment procedures.
Jeffrey W Koehler, Adrienne T Hall, P Alexander Rolfe, Anna N Honko, Gustavo F Palacios, Joseph N Fair, Jean-Jacques Muyembe, Prime Mulembekani, Randal J Schoepp, Adeyemi Adesokan, Timothy D Minogue   +10 more
doaj   +1 more source

A SOME ECOLOGICAL CHARACTERISTICS OF EBOLA VIRUS IN NATURAL FOCIES

Журнал микробиологии, эпидемиологии и иммунобиологии, 2018
Ebola virus that composed Ebolavirus genus of Filoviridae Family causes severe hemorrhagic fever in humans with high case-fatality rates (up to 90%).
T. E. Sizikova, V. N. Lebedev, N. V. Karulina, O. V. Chukhralya, S. I. Syromyatnikova, S. V. Borisevich   +5 more
doaj   +1 more source

Structural Basis of Pan-Ebolavirus Neutralization by a Human Antibody against a Conserved, yet Cryptic Epitope

mBio, 2018
Only one naturally occurring human antibody has been described thus far that is capable of potently neutralizing all five ebolaviruses. Here we present two crystal structures of this rare, pan-ebolavirus neutralizing human antibody in complex with Ebola ...
Brandyn R. West, Crystal L. Moyer, Liam B. King, Marnie L. Fusco, Jacob C. Milligan, Sean Hui, Erica Ollmann Saphire   +6 more
doaj   +1 more source

Clock-like behavior across Orthoebolavirus species suggests alternative evolution of the 2026 Bundibugyo virus outbreak

Journal of Infection in Developing Countries
Introduction: Recent increase in reported cases of Bundibugyo virus (species Orthoebolavirus bundibugyoense) in the Democratic Republic of the Congo and Uganda highlight the importance of understanding their evolutionary dynamics.
Gustavo Sganzerla Martinez, Anuj Kumar, Mansi Dutt, Misaki Wayengera, Wilber Sabiiti, David J Kelvin, Henry Kyobe Bosa   +6 more
doaj   +1 more source

The 2026 Bundibugyo virus disease outbreak in the Democratic Republic of the Congo: Virology, epidemiology, continental response, and research priorities

Infectious Medicine
Bundibugyo ebolavirus (BDBV), a member of the genus Orthoebolavirus , family Filoviridae , is hereafter referred to as Bundibugyo virus, with the associated illness termed Bundibugyo virus disease (BVD).
Yi Zhang, Junkai Ren, Xuejun Ma, Xiaozhou He   +3 more
doaj   +1 more source

Species breadth is a preparedness metric: lessons from the 2026 Bundibugyo virus disease outbreak

Emerging Microbes and Infections
Recent outbreaks of non-Zaire orthoebolaviruses have exposed a persistent weakness in outbreak preparedness: diagnostic, vaccine, therapeutic, regulatory, and research systems remain disproportionately optimized for Ebola virus (EBOV).
Ayan Mohamed Hassan, Abdullahi Abdi Yusuf, Adan Mohamed Hirsi, Ilyas Abdullahi Khalif, Ayaan Axmed Maxamed, Deka Ahmed Abdi   +5 more
doaj   +1 more source

Structural Basis of Pan-Ebolavirus Neutralization by an Antibody Targeting the Glycoprotein Fusion Loop

Cell Reports, 2018
Summary: Monoclonal antibodies (mAbs) with pan-ebolavirus cross-reactivity are highly desirable, but development of such mAbs is limited by a lack of a molecular understanding of cross-reactive epitopes.
Charles D. Murin, Jessica F. Bruhn, Zachary A. Bornholdt, Jeffrey Copps, Robyn Stanfield, Andrew B. Ward   +5 more
doaj   +1 more source

Repurposed Medicines for Viruses With Epidemic or Pandemic Potential: A Horizon Scan

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT Viruses such as Ebola, Marburg, influenza, mpox, MERS‐CoV, SARS‐CoV, and SARS‐CoV‐2 may be considered pathogens of epidemic or pandemic concern. Developing novel antiviral medicines can be time‐consuming and resource intensive. Repurposing existing medicines with known or potential antiviral activity offers a faster, cost‐effective strategy to
Sola Akinbolade, Rhiannon Potter, Alex Inskip, Jane Nesworthy, Kirsti Brock, Gill Norman   +5 more
wiley   +1 more source